300871.SHE Wuhan Hvsen Biotechnology Co Ltd
- Market cap
- CNY 3.41B
- P/E
- 10.8x
- P/B
- 1.45x
- ROE
- 15.0%
- Dividend yield
- 1.46%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300871.SHE undervalued?
Graham number300871.SHE trades 16.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Wuhan Hvsen Biotechnology Co Ltd fundamental analysis
No fundamental analysis for Wuhan Hvsen Biotechnology Co Ltd yet.
Wuhan Hvsen Biotechnology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Wuhan Hvsen Biotechnology Co Ltd
Wuhan Hvsen Biotechnology Co.,Ltd. is involved in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company provides tylvalosin tartrate powders, and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products, as well as Tildipirosin. It produces various veterinary drug products of raw materials and prepa…
Full company profileWuhan Hvsen Biotechnology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Wuhan Hvsen Biotechnology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 258M | 400M | 422M | 427M | 777M | 996M | 1.02B | 1.02B | 1.20B | 1.68B | 1.71B |
| Gross Profit | 134M | 202M | 183M | 162M | 286M | 269M | 223M | 211M | 195M | 521M | 577M |
| Operating Income | 54.5M | 103M | 81.5M | 78.6M | 177M | 151M | 59.2M | 15.1M | -29.1M | 302M | 326M |
| EBITDA | 65.5M | 114M | 94.8M | 92.9M | 198M | 182M | 138M | 161M | 127M | 423M | 392M |
| Net Income | 49.4M | 88.4M | 71.4M | 68.8M | 150M | 133M | 52.7M | 16.8M | -20.2M | 253M | 345M |
| EPS | 0.43 | 0.74 | 0.59 | 0.55 | 1.02 | 0.80 | 0.32 | 0.10 | -0.12 | 1.25 | 1.71 |
| Balance Sheet | |||||||||||
| Total Assets | 256M | 344M | 467M | 650M | 1.75B | 2.74B | 2.99B | 2.98B | 3.01B | 3.01B | 3.40B |
| Total Liabilities | 101M | 121M | 142M | 272M | 373M | 1.12B | 1.45B | 1.47B | 1.55B | 822M | 1.08B |
| Shareholders' Equity | 155M | 223M | 325M | 378M | 1.38B | 1.62B | 1.54B | 1.51B | 1.46B | 2.17B | 2.31B |
| Cash & Short-term Investments | 52.3M | 53.4M | 99.5M | 104M | 586M | 1.10B | 786M | 598M | 527M | 310M | 263M |
| Total Debt | 1.00M | 1.00M | 25.0M | 75.6M | 72.7M | 681M | 790M | 842M | 872M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 60.0M | 80.6M | 21.1M | 105M | 48.3M | 156M | 96.7M | 92.9M | 43.5M | 238M | - |
| Capital Expenditure | 28.0M | 56.4M | 34.1M | 123M | 231M | 600M | 429M | 184M | 194M | 96.9M | 524M |
| Free Cash Flow | 32.0M | 24.2M | -13.0M | -17.8M | -182M | -444M | -332M | -91.4M | -151M | 142M | -259M |
| Ratios | |||||||||||
| ROE | 32.0% | 39.6% | 22.0% | 18.2% | 10.9% | 8.2% | 3.4% | 1.1% | -1.4% | 11.6% | 15.0% |
| ROA | 19.3% | 25.7% | 15.3% | 10.6% | 8.6% | 4.8% | 1.8% | 0.6% | -0.7% | 8.4% | 10.2% |
| Net Profit Margin | 19.2% | 22.1% | 16.9% | 16.1% | 19.3% | 13.3% | 5.2% | 1.6% | -1.7% | 15.1% | 20.1% |
| Debt to Equity | 0.01x | 0.00x | 0.08x | 0.20x | 0.05x | 0.42x | 0.51x | 0.56x | 0.60x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Wuhan Hvsen Biotechnology Co Ltd dividends
- Dividend yield
- 1.46%
- Forward dividend
- 0.50 CNY
- Payout ratio
- 19.7%
- Ex-dividend date
- Sep 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 49.9M | 0.25 | 19.7% |
| 2024 | CNY 59.2M | 0.36 | - |
| 2023 | CNY 49.0M | 0.30 | 291.8% |
| 2022 | CNY 54.9M | 0.33 | 104.2% |
| 2021 | CNY 45.3M | 0.27 | 34.1% |
| 2020 | CNY 5.99M | 0.04 | 4.0% |
| 2019 | CNY 15.0M | 0.12 | 21.8% |
| 2018 | CNY 21.6M | 0.18 | 30.3% |
| 2017 | CNY 24.4M | 0.20 | 27.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on May 10, 2021.
Who owns Wuhan Hvsen Biotechnology Co Ltd
- Insiders 47.32%
- Institutions 3.48%
- Public & others 49.20%
- Shares outstanding 202M
- Free float 104M
Wuhan Hvsen Biotechnology Co Ltd company profile
- Company name
- Wuhan Hvsen Biotechnology Co Ltd
- Ticker
- 300871.SHE
- ISIN
- CNE1000047H6
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,133
- Fiscal year end
- December
- Address
- No.208 Zhangbai Road, Wuhan, China, 430042
- Phone
- 86 27 8860 5516
- Website
- whhsyy.com
About Wuhan Hvsen Biotechnology Co Ltd
Wuhan Hvsen Biotechnology Co.,Ltd. is involved in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company provides tylvalosin tartrate powders, and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products, as well as Tildipirosin. It produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Biotechnology Co., Ltd. was founded in 2002 and is based in Wuhan, China.
Wuhan Hvsen Biotechnology Co Ltd management
10- Mr. Jie HanGeneral Manager · born 1985
- Mr. Kaijie YangDeputy GM & CFO · born 1970
- Mr. Zexiang LiuDirector & Assistant to the GM · born 1976
- Mr. Qingfeng WangBoard Secretary · born 1989
- Mr. Jinbin HuangDeputy General Manager · born 1982
- Mr. Shuo LiDeputy General Manager · born 1980
- Mr. Hujie YuDeputy General Manager · born 1985
- Qiongbi LuoAccounting Supervisor
- Ms. Hongxia LiDirector of Warehousing & Logistics Data and Supervisor · born 1976
- Mr. Wenge DingProduct & Technical Service Director and Supervisor · born 1969